These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38335502)

  • 1. ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.
    Forster-Sack M; Zoche M; Pestalozzi B; Witzel I; Schwarz EI; Herzig JJ; Fansa H; Tausch C; Ross J; Moch H; Varga Z
    J Pathol Clin Res; 2024 Mar; 10(2):e12362. PubMed ID: 38335502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling.
    Christgen M; Bartels S; Radner M; Raap M; Rieger L; Christgen H; Gluz O; Nitz U; Harbeck N; Lehmann U; Kreipe H
    Genes Chromosomes Cancer; 2019 Mar; 58(3):175-185. PubMed ID: 30520184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Characterization of Primary Invasive Lobular Breast Cancer.
    Desmedt C; Zoppoli G; Gundem G; Pruneri G; Larsimont D; Fornili M; Fumagalli D; Brown D; Rothé F; Vincent D; Kheddoumi N; Rouas G; Majjaj S; Brohée S; Van Loo P; Maisonneuve P; Salgado R; Van Brussel T; Lambrechts D; Bose R; Metzger O; Galant C; Bertucci F; Piccart-Gebhart M; Viale G; Biganzoli E; Campbell PJ; Sotiriou C
    J Clin Oncol; 2016 Jun; 34(16):1872-81. PubMed ID: 26926684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
    Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
    Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
    Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
    Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
    Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
    Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements.
    Christgen M; Bartels S; van Luttikhuizen JL; Bublitz J; Rieger LU; Christgen H; Stark H; Sander B; Lehmann U; Steinemann D; Derksen PWB; Kreipe H
    Mod Pathol; 2020 Dec; 33(12):2483-2498. PubMed ID: 32572153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
    Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
    Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
    Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.
    Lien HC; Chen YL; Juang YL; Jeng YM
    Breast Cancer Res Treat; 2015 Apr; 150(2):447-55. PubMed ID: 25773929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic PIK3CA mutations in lobular breast cancer progression.
    Christgen M; Noskowicz M; Schipper E; Christgen H; Heil C; Krech T; Länger F; Kreipe H; Lehmann U
    Genes Chromosomes Cancer; 2013 Jan; 52(1):69-80. PubMed ID: 22997091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lobular breast cancer: Clinical, molecular and morphological characteristics.
    Christgen M; Steinemann D; Kühnle E; Länger F; Gluz O; Harbeck N; Kreipe H
    Pathol Res Pract; 2016 Jul; 212(7):583-97. PubMed ID: 27233940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.
    Owens MA; Horten BC; Da Silva MM
    Clin Breast Cancer; 2004 Apr; 5(1):63-9. PubMed ID: 15140287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.
    Deniziaut G; Tille JC; Bidard FC; Vacher S; Schnitzler A; Chemlali W; Trémoulet L; Fuhrmann L; Cottu P; Rouzier R; Bièche I; Vincent-Salomon A
    Oncotarget; 2016 Nov; 7(45):73337-73346. PubMed ID: 27602491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive genetic and functional characterization of IPH-926: a novel CDH1-null tumour cell line from human lobular breast cancer.
    Christgen M; Bruchhardt H; Hadamitzky C; Rudolph C; Steinemann D; Gadzicki D; Hasemeier B; Römermann D; Focken T; Krech T; Ballmaier M; Schlegelberger B; Kreipe H; Lehmann U
    J Pathol; 2009 Apr; 217(5):620-32. PubMed ID: 19191266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
    Ferguson DC; Momeni Boroujeni A; Zheng T; Mohanty AS; Ho AL; Arcila ME; Ross DS; Dogan S
    Mod Pathol; 2022 Jul; 35(7):895-902. PubMed ID: 34963694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.
    Christgen M; Bartels S; Luft A; Persing S; Henkel D; Lehmann U; Kreipe H
    Virchows Arch; 2018 Nov; 473(5):577-582. PubMed ID: 30094493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.